TG Therapeutics, Inc. (LON:0VGI)

TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of GBP 3.66 billion. The enterprise value is 3.66 billion.

Market Cap	3.66B
Enterprise Value	3.66B

Important Dates

The next estimated earnings date is Tuesday, November 4, 2025.

Earnings Date	Nov 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	145.90M
Shares Outstanding	n/a
Shares Change (YoY)	+11.99%
Shares Change (QoQ)	-0.13%
Owned by Insiders (%)	7.32%
Owned by Institutions (%)	72.74%
Float	135.16M

Valuation Ratios

The trailing PE ratio is 82.84 and the forward PE ratio is 21.40.

PE Ratio	82.84
Forward PE	21.40
PS Ratio	11.03
PB Ratio	18.12
P/TBV Ratio	18.12
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 55.29, with an EV/FCF ratio of -84.59.

EV / Earnings	82.88
EV / Sales	10.72
EV / EBITDA	55.29
EV / EBIT	56.68
EV / FCF	-84.59

Financial Position

The company has a current ratio of 3.86, with a Debt / Equity ratio of 0.92.

Current Ratio	3.86
Quick Ratio	2.81
Debt / Equity	0.92
Debt / EBITDA	2.89
Debt / FCF	-4.30
Interest Coverage	2.75

Financial Efficiency

Return on equity (ROE) is 26.63% and return on invested capital (ROIC) is 13.06%.

Return on Equity (ROE)	26.63%
Return on Assets (ROA)	9.72%
Return on Invested Capital (ROIC)	13.06%
Return on Capital Employed (ROCE)	16.18%
Revenue Per Employee	895,743
Profits Per Employee	119,266
Employee Count	338
Asset Turnover	0.82
Inventory Turnover	0.50

Taxes

In the past 12 months, TG Therapeutics has paid 4.12 million in taxes.

Income Tax	4.12M
Effective Tax Rate	8.55%

Stock Price Statistics

The stock price has increased by +56.36% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+56.36%
50-Day Moving Average	32.06
200-Day Moving Average	23.84
Relative Strength Index (RSI)	58.10
Average Volume (20 Days)	3,895

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.85

Income Statement

In the last 12 months, TG Therapeutics had revenue of GBP 331.42 million and earned 44.13 million in profits. Earnings per share was 0.26.

Revenue	331.42M
Gross Profit	288.20M
Operating Income	62.66M
Pretax Income	48.25M
Net Income	44.13M
EBITDA	62.69M
EBIT	62.66M
Earnings Per Share (EPS)	0.26

Balance Sheet

The company has 183.84 million in cash and 185.78 million in debt, giving a net cash position of -1.94 million.

Cash & Cash Equivalents	183.84M
Total Debt	185.78M
Net Cash	-1.94M
Net Cash Per Share	n/a
Equity (Book Value)	201.77M
Book Value Per Share	1.39
Working Capital	359.16M

Cash Flow

In the last 12 months, operating cash flow was -43.16 million and capital expenditures -81,749, giving a free cash flow of -43.24 million.

Operating Cash Flow	-43.16M
Capital Expenditures	-81,749
Free Cash Flow	-43.24M
FCF Per Share	n/a

Margins

Gross margin is 86.96%, with operating and profit margins of 18.91% and 13.31%.

Gross Margin	86.96%
Operating Margin	18.91%
Pretax Margin	14.56%
Profit Margin	13.31%
EBITDA Margin	18.92%
EBIT Margin	18.91%
FCF Margin	n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.99%
Shareholder Yield	-11.99%
Earnings Yield	1.21%
FCF Yield	-1.18%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TG Therapeutics has an Altman Z-Score of 5.1 and a Piotroski F-Score of 3.

Altman Z-Score	5.1
Piotroski F-Score	3